Berger really fumbled the FDA shutdown of Ponatinib. There were clear signs of SAE issues and the management team, led by Harvey, miscalculated the FDA response. That indicated to me that he is not a smart manager and is not equipped to bring true value to the stock. Intelligence doesn't equate to business savvy or people skills. Hope he leaves when he sees the fight for control is a losing battle.
News 
Market Data 
Discover 
